Abstract
The peroxovanadium compound VO(O2)2, 1,10 phenanthroline (bpV (phen)) is capable of lowering blood glucose levels. It is not available in oral form, but it is effective when delivered transdermally. Iontophoresis can significantly reduce the lag time of this response in vivo when compared with passive penetration. To better mimic in vivo insulin release, we explored the effects of various iontophoretic current durations on dermal penetration of bpV(phen). Iontophoretic transport was not related to total applied charge, as steady-state flux was equivalent for current durations ranging from 15 minutes to 9 hours. We hypothesized that the unexpectedly large transport after just 15 minutes of current was caused by an increase in passive penetration of bpV(phen) induced by iontophoresis. Iontophoretic pretreatment with the chelating agent 1,10 phenanthroline increased passive penetration of bpV(phen), whereas neither the nonchelating isomer 1,7 phenanthroline nor the less potent chelator EDTA were effective. The use of 1,10 phenanthroline as a penetration enhancer for other chemicals was examined with the amino acids alanine and leucine. Fifteen minutes of 1,10 phenanthroline iontophoresis enhances alanine transport 11.4-fold over passive, whereas the 1,7 phenanthroline increased transport by a factor of 4.6 and the iontophoretic control of ethanol by 1.9. Surprisingly, phenanthroline did not enhance 3H leucine penetration. The reasons for this selectivity are not clear and warrent further investigation. Overall, the data suggest that chelating agents, specifically 1,10 phenanthroline, may be used as penetration enhancers for the delivery of certain compounds.
KeyWords: Transdermal, Skin, Iontophoresis, Vanadium, Diabetes
References
- 1.Bevan AP, Burgess JW, Yale JF, et al. in vivo insulin mimetic effects of pV compounds role for tissue targeting. Am J Physiol. 1995;268:E60–66. doi: 10.1152/ajpendo.1995.268.1.E60. [DOI] [PubMed] [Google Scholar]
- 2.Posner BI, Faure R, Burgess JW, et al. Peroxovanadium compounds, a new class of potent phosphotyrosine phosphatase inhibitors which are unsulin mimetics. J Biol Chem. 1994;296:4596–4604. [PubMed] [Google Scholar]
- 3.Brand RM, Hamel FG. Transdermally delivered peroxovanadium can lower blood glucose levels in diabetic rats. Int J Pharm. 1999;183:117–123. doi: 10.1016/S0378-5173(99)00071-X. [DOI] [PubMed] [Google Scholar]
- 4.Brand RM, Duensing G, Hamel FG. Iontophoretic delivery of an insulin-mimetic peroxovanadium compound. Int J Pharm. 1997;146:115–122. doi: 10.1016/S0378-5173(96)04781-3. [DOI] [Google Scholar]
- 5.Ledger PW. Skin biological issues in electrically enhanced transdermal delivery. Adv Drug Del Rev. 1992;9:289–307. doi: 10.1016/0169-409X(92)90027-N. [DOI] [Google Scholar]
- 6.Kim A, Green PG, Rao G, Guy RH. Convective solvent flow across the skin during iontophoresis. Pharm Res. 1993;10:1315–1320. doi: 10.1023/A:1018969713547. [DOI] [PubMed] [Google Scholar]
- 7.Phipps JB, Gyory JR. Transdermal ion migration. Adv Drug Del Rev. 1992;9:137–176. doi: 10.1016/0169-409X(92)90022-I. [DOI] [Google Scholar]
- 8.Singh P, Maibach HI. Ionrophoresis: an alternative to the use of carriers in cutaneous drug delivery. Adv Drug Del Rev. 1996;18:379–394. doi: 10.1016/0169-409X(95)00082-I. [DOI] [Google Scholar]
- 9.Delgado-Charro MB, Guy RH. Intophoretic delivery of nafarelin across the skin. Int JPharma. 1995;117:165–172. doi: 10.1016/0378-5173(94)00323-W. [DOI] [Google Scholar]
- 10.Knoblauch P, Moll F. In vitro pulsatile and continuous transdermal delivery of buserelin by iontophoresis. J Control Release. 1993;26:203–212. doi: 10.1016/0168-3659(93)90187-A. [DOI] [Google Scholar]
- 11.Nakakura M, Terajima M, Kato Y, Hayakawa E, Ito K, Kuroda T. Effect of iontophoretic patterns on in vivo antidiuretic response to desmopressin acetate administered transdermally. J Drug Target. 1995;2:487–492. doi: 10.3109/10611869509015918. [DOI] [PubMed] [Google Scholar]
- 12.Prausnitz MR. The effects of electric current applied to skin: a review for transdermal drug delivery. Adv Drug Del Rev. 1996;18:395–425. doi: 10.1016/0169-409X(95)00081-H. [DOI] [Google Scholar]
- 13.Hirvonen J, Hueber F, Guy RH. Current profile regulates iontophoretic delivery of amino acids across the skin. J Control Release. 1995;37:239–249. doi: 10.1016/0168-3659(95)00081-X. [DOI] [Google Scholar]
- 14.Turner NG, Kalia YN, Guy RH. The effect of current on skin barrier function in vivo: recovery kinetics post-iontophoresis. Pharm Res. 1997;14:1252–1257. doi: 10.1023/A:1012175428181. [DOI] [PubMed] [Google Scholar]
- 15.Chiang CH, Shao CH, Chen JL. Effects of pH, electric current, and enzyme inhibitors on iontophoresis of delta sleep-inducing peptide. Drug Dev. Indus. Pharm. 1998;24:431–438. doi: 10.3109/03639049809085640. [DOI] [PubMed] [Google Scholar]